D-Index & Metrics Best Publications
Research.com 2022 Rising Star of Science Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 71 Citations 18,725 286 World Ranking 14979 National Ranking 555
Rising Stars D-index 71 Citations 18,727 279 World Ranking 41 National Ranking 1

Research.com Recognitions

Awards & Achievements

2022 - Research.com Rising Star of Science Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Melanoma

Internal medicine, Melanoma, Ipilimumab, Oncology and Pembrolizumab are his primary areas of study. His biological study spans a wide range of topics, including Surgery and Immunology. His Melanoma research integrates issues from Cancer and Immunotherapy.

His study in Cancer is interdisciplinary in nature, drawing from both Biopsy and Pathology. His studies in Ipilimumab integrate themes in fields like Discontinuation and Response Evaluation Criteria in Solid Tumors. He interconnects Biomarker, V600E and Hazard ratio in the investigation of issues within Oncology.

His most cited work include:

  • Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma (758 citations)
  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (538 citations)
  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy (436 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Ipilimumab and Immunotherapy. The Melanoma study combines topics in areas such as Cancer, Targeted therapy and Immunology. Many of his studies on Internal medicine apply to Gastroenterology as well.

His studies deal with areas such as Adjuvant therapy, Metastatic melanoma, Surgery and Cohort as well as Oncology. His Ipilimumab research is multidisciplinary, incorporating perspectives in Advanced melanoma, Adjuvant, Clinical endpoint, Toxicity and Combination therapy. His Adverse effect research is multidisciplinary, incorporating elements of Immunosuppression and Discontinuation.

He most often published in these fields:

  • Melanoma (100.31%)
  • Internal medicine (96.59%)
  • Oncology (67.49%)

What were the highlights of his more recent work (between 2020-2021)?

  • Internal medicine (96.59%)
  • Melanoma (100.31%)
  • Oncology (67.49%)

In recent papers he was focusing on the following fields of study:

Alexander M. Menzies mainly focuses on Internal medicine, Melanoma, Oncology, Ipilimumab and Nivolumab. He usually deals with Internal medicine and limits it to topics linked to Gastroenterology and Adverse effect and Immunosuppression. His Melanoma research includes themes of Immune checkpoint, Targeted therapy, Interquartile range and Confidence interval.

His research in Oncology focuses on subjects like Metastatic melanoma, which are connected to PALB2, Mutation, Partial response and Somatic cell. The various areas that he examines in his Ipilimumab study include Pembrolizumab, Metastasis and Systemic therapy. The study incorporates disciplines such as Neoadjuvant therapy and Clinical trial in addition to Nivolumab.

Between 2020 and 2021, his most popular works were:

  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). (8 citations)
  • Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). (8 citations)
  • Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. (4 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His main research concerns Internal medicine, Melanoma, Ipilimumab, Nivolumab and Oncology. Retrospective cohort study and Cohort study are among the areas of Internal medicine where the researcher is concentrating his efforts. His work is dedicated to discovering how Retrospective cohort study, Cause of death are connected with Cancer and other disciplines.

He interconnects Positron emission tomography and Histopathology in the investigation of issues within Melanoma. His work deals with themes such as Pembrolizumab and Systemic therapy, which intersect with Ipilimumab. His Nivolumab study which covers Targeted therapy that intersects with Clinical trial, Surrogate endpoint and Neoadjuvant therapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu.
Journal of Clinical Oncology (2011)

1044 Citations

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra.
JAMA Oncology (2018)

667 Citations

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz.
Journal of Clinical Oncology (2017)

591 Citations

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson.
Annals of Oncology (2016)

505 Citations

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

Georgina V Long;Victoria Atkinson;Serigne Lo;Shahneen Sandhu.
Lancet Oncology (2018)

459 Citations

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino.
JAMA Oncology (2016)

429 Citations

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

Alexander M. Menzies;Lauren E. Haydu;Lydia Visintin;Lydia Visintin;Lydia Visintin;Matteo S. Carlino;Matteo S. Carlino.
Clinical Cancer Research (2012)

416 Citations

BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact.

Helen Rizos;Alexander M. Menzies;Gulietta M. Pupo;Matteo S. Carlino.
Clinical Cancer Research (2014)

392 Citations

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Jason Madore;Ricardo E. Vilain;Ricardo E. Vilain;Alexander M. Menzies;Hojabr Kakavand.
Pigment Cell & Melanoma Research (2015)

388 Citations

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak.
Lancet Oncology (2018)

305 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Alexander M. Menzies

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 148

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 138

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 103

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 99

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 93

Grant A. McArthur

Grant A. McArthur

Peter MacCallum Cancer Centre

Publications: 89

Douglas B. Johnson

Douglas B. Johnson

Vanderbilt University Medical Center

Publications: 87

Caroline Robert

Caroline Robert

Institut Gustave Roussy

Publications: 81

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 81

James Larkin

James Larkin

Royal Marsden NHS Foundation Trust

Publications: 69

John F. Thompson

John F. Thompson

University of Sydney

Publications: 65

Céleste Lebbé

Céleste Lebbé

Université Paris Cité

Publications: 64

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 62

Michael A. Davies

Michael A. Davies

The University of Texas MD Anderson Cancer Center

Publications: 60

Michael A. Postow

Michael A. Postow

Memorial Sloan Kettering Cancer Center

Publications: 59

Claus Garbe

Claus Garbe

University of Tübingen

Publications: 57

Something went wrong. Please try again later.